Physician profile
Rajeev Manu
NPI 1003899907
$2,234.40
in general payments reported to CMS, 2019-2025
19 companies · $281 in 2025
The $281 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $203 · 2020: $37.86 · 2021: $276 · 2022: $341 · 2023: $527 · 2024: $570 · 2025: $281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,376.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,154.89 | 2019-2025 | Exalt Model D, General - Biliary Devices, Apollo Esg Nxt System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $215.72 | 2023-2025 | Xifaxan, Plenvu, Trulance |
| Intercept Pharmaceuticals, INC. | $182.71 | 2019-2023 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $148.54 | 2024-2025 | Voquezna |
| Abbvie INC. | $108.55 | 2021-2022 | |
| Janssen Biotech, INC. | $107.39 | 2019-2025 | Simponi, Stelara, Tremfya |
| Ardelyx, INC. | $52.00 | 2023 | Ibsrela |
| Daiichi Sankyo INC. | $50.56 | 2019-2021 | |
| Albireo Pharma, INC. | $28.49 | 2024 | Bylvay |
| Regeneron Healthcare Solutions, INC. | $27.78 | 2022 | |
| Lucid Diagnostics INC. | $21.96 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $21.65 | 2025 | |
| Concordia Pharmaceuticals INC. | $19.33 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $18.58 | 2025 | |
| Merck Sharp & Dohme LLC | $17.85 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirum Pharmaceuticals, INC. | $17.59 | 2024 | Livmarli |
| Aimmune Therapeutics, INC. | $14.93 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.63 | 2020 | |
| Ethicon US, LLC | $12.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajeev Manu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.